|
C8ORF39 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.21200000041877E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.80679999997702E-06 |
| Normal-vs-Stage2 |
1.677099999986E-07 |
| Normal-vs-Stage3 |
2.28790000278423E-08 |
| Normal-vs-Stage4 |
2.19040000004611E-06 |
| Stage1-vs-Stage2 |
7.442400E-02 |
| Stage1-vs-Stage3 |
8.142500E-03 |
| Stage1-vs-Stage4 |
3.547800E-01 |
| Stage2-vs-Stage3 |
8.316600E-01 |
| Stage2-vs-Stage4 |
6.060000E-01 |
| Stage3-vs-Stage4 |
4.035000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.05149999993526E-07 |
| Normal-vs-AfricanAmerican |
1.856120E-02 |
| Normal-vs-Asian |
4.05830000049789E-07 |
| Caucasian-vs-AfricanAmerican |
2.647200E-01 |
| Caucasian-vs-Asian |
5.198000E-01 |
| AfricanAmerican-vs-Asian |
1.720170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.06609999994678E-06 |
| Normal-vs-Female |
3.19169999984936E-07 |
| Male-vs-Female |
8.452200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.15360000002762E-06 |
| Normal-vs-Age(41-60Yrs) |
2.784799999489E-07 |
| Normal-vs-Age(61-80Yrs) |
3.36329999961471E-07 |
| Normal-vs-Age(81-100Yrs) |
2.08180000005331E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.535400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.613200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.393820E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.864200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.616400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.425400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.408310E-04 |
| Classical-VS-Follicular |
8.429500E-02 |
| Classical-VS-Other |
5.480000E-01 |
| Classical-VS-Normal |
3.58739999994917E-06 |
| Tall-VS-Follicular |
5.199600E-02 |
| Tall-VS-Other |
2.683800E-01 |
| Tall-VS-Normal |
1.5240999573507E-09 |
| Follicular-VS-Other |
9.885000E-01 |
| Follicular-VS-Normal |
3.55720000011495E-07 |
| Other-VS-Normal |
2.440100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.21699999972225E-07 |
| Normal-vs-N1 |
3.515100E-03 |
| N0-vs-N1 |
1.453980E-02 |
|
|
